JP Morgan Chase
RNTX

JP Morgan Chase’s Rein Therapeutics RNTX Stock Holding History

JP Morgan Chase’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32
Closed -$57 – 7822
2025
Q1 		$57 Buy
32
+2
+7% +$4 ﹤0.01% 6965
2024
Q4 		$69 Buy
+30
New +$91 ﹤0.01% 7065
2022
Q2 		– Sell
-55
Closed -$1K – 6962
2022
Q1 		$1K Buy
+55
New +$498 ﹤0.01% 6505
2018
Q2 		– Sell
-54
Closed -$9K – 5728
2018
Q1 		$9K Buy
54
+12
+29% +$2.14K ﹤0.01% 5189
2017
Q4 		$9K Buy
+42
New +$10.1K ﹤0.01% 5273

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

JP Morgan Chase's RNTX Position: Q2 2025 in Review

JP Morgan Chase sold out of Rein Therapeutics (RNTX) in Q2 2025, closing a stake of 32 shares — an estimated $57 sold.

JP Morgan Chase first reported a position in RNTX in Q4 2017 and held it in 5 quarters. The position peaked at $9K in Q1 2018. 36 funds tracked by Wall St. Rank hold RNTX as of Q2 2025.

  • JP Morgan Chase reported no remaining Rein Therapeutics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 32 Rein Therapeutics shares in Q2 2025, an estimated $57.
  • JP Morgan Chase first reported a position in Rein Therapeutics in Q4 2017 and held it in 5 quarters.
  • JP Morgan Chase's Rein Therapeutics position peaked at $9K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.